Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly. Its lead candidate, ivonescimab, is a first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF pathways, advancing immunotherapy combined with anti-angiogenesis for oncology applications. The company is conducting multiple Phase III clinical trials evaluating ivonescimab, including in combination with chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) after third-generation TKI therapy, first-line metastatic NSCLC, squamous NSCLC, and first-line unresectable metastatic colorectal cancer. Summit Therapeutics Inc. also pursues collaborations, such as with GSK to combine ivonescimab with investigational therapies in solid tumors including small cell lung cancer. These efforts target serious unmet needs in oncology, particularly lung and colorectal cancers. Founded in 2003 and headquartered in Miami, Florida, Summit Therapeutics Inc. operates in the biotechnology sector with a pipeline centered on next-generation cancer treatments.